Cell-free DNA (cfDNA) testing company Natera is launching a study this year of its Signatera blood test in patients with stage II/III colorectal cancer to assess its value in molecular residual disease assessment and clinical outcomes.
The multicenter, registry study -- dubbed BESPOKE -- is slated to include 1,000 participants in the adjuvant setting. The protocol calls for serial testing in the months after surgery to provide information on several fronts, including whether adjuvant chemotherapy is needed, the likelihood and detection of relapse, and whether a curative treatment regimen is available based on individual characteristics.
The California-based company noted that Signatera has detected relapse in patients with stage II/III colorectal cancer up to 16.5 months earlier than other diagnostic tools, such as computed tomography (CT) scans and carcinoembryonic antigen (CEA) blood testing.
Natera said it expects to complete the study in 2023.